Parallax Volatility Advisers
NKGN

Parallax Volatility Advisers’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Parallax Volatility Advisers’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-164,071
Closed -$1.59M – 3449
2022
Q2 		$1.59M Buy
+164,071
New +$1.6M ﹤0.01% 1449

Other funds holding NKGN

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Parallax Volatility Advisers's NKGN Position: Q3 2022 in Review

Parallax Volatility Advisers sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q3 2022, closing a stake of 164,071 shares — an estimated $1.59M sold.

Parallax Volatility Advisers first reported a position in NKGN in Q2 2022 and held it in 1 quarter. The position peaked at $1.59M in Q2 2022. 53 funds tracked by Wall St. Rank hold NKGN as of Q3 2022.

  • Parallax Volatility Advisers reported no remaining NKGen Biotech, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 164,071 NKGen Biotech, Inc. Common Stock shares in Q3 2022, an estimated $1.59M.
  • Parallax Volatility Advisers first reported a position in NKGen Biotech, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Parallax Volatility Advisers's NKGen Biotech, Inc. Common Stock position peaked at $1.59M in Q2 2022.
  • 53 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q3 2022.

Based on Parallax Volatility Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.